The first thing to realize is that the emergence of the novel coronavirus isn’t a rare “black swan” event. Rather, this is a product of evolution; there have been about 40 new, infectious diseases discovered globally since the 1970s, with pathogens often jumping from animals to humans.

Detecting who has this new virus becomes a key public health challenge, which is made harder because it’s the season for another virus – influenza. And in the U.S., there is a shortage of local laboratories able to test for the coronavirus virus in humans.

Influenza, by contrast, is far more familiar to public health researchers and doctors, and thus more predictable. It can occur anytime during the year in the U.S., but it typically begins in September and can go into May of the following year. While the peak of cases in the U.S. fluctuates, it typically occurs in February when the disease is widespread across the country.

If a new disease emerges during influenza season and has different signs and symptoms than the influenza, then it is easier to detect and track in the human population. However, if the signs and symptoms overlap, as they do with flu and COVID-19, detection is much more difficult for the public health, medical and the lay population.

COVID-19 produces signs and symptoms that are similar to influenza, which makes it difficult to distinguish between the two. COVID-19 can cause fever, cough, body aches, fatigue and, occasionally, vomiting and diarrhea; both can cause pneumonia as well.

Speed of spread

Currently one of the biggest differences between seasonal influenza and COVID-19 is the incubation period – that is, the time from exposure to development of signs and symptoms. For seasonal influenza, the incubation period ranges from one to four days, but in some instances, people may be contagious a day before symptoms appear and as long as five to seven days after symptoms start. COVID-19’s incubation period ranges from 2-14 days, which is up to three times longer than influenza.

Also, COVID-19 is more contagious than seasonal influenza. The average person, even with mild symptoms, is likely to spread the disease to more than two people. By contrast, the seasonal flu’s rate is roughly half.

Another significant challenge with influenza and COVID-19 is that they both can have mild infections. People with more mild disease are less likely to seek diagnosis and care, but are still considered infectious and able to transmit the disease person to person.

Finally, one of the biggest concerns for COVID-19 is asymptomatic infections. People who are infected with the virus may be able to transmit the infection, and yet they themselves don’t have any signs or symptoms of disease. This represents a challenge because it would be difficult to identify persons that need to be tested for the disease since they have no signs or symptoms, but their ability to transmit the disease would allow for amplification in a naive, or uninfected, population.

No vaccine available for COVID-19

Unlike influenza, COVID-19 does not have a vaccine or medication people can take to protect themselves and it is believed that everyone is susceptible.

There are a number of efforts to develop treatments for COVID-19, but nothing is yet approved. Vaccines are also being pursued, but a vaccine for COVID-19 will not be ready for several months.

Getting the vaccine for the seasonal flu can actually be helpful for medical professionals. Since the signs and symptoms are similar, if everyone were to be vaccinated against the flu, fewer people would have the flu, thus making it easier to detect another disease with similar symptoms. The faster it is identified, the faster public health and the medical community can respond to minimize the spread of disease.

Share

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.